Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10357486 | 0.81 | KDM4C (0.44) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL2644185 | 0.81 | KMT2A (0.51) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL26982209 | 0.80 | KDM4C (0.49) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL971208 | 0.80 | KDM4C (0.45) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL12574506 | 0.78 | ACACB (0.35) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL15244186 | 0.78 | KDM4C (0.47) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL30570058 | 0.76 | KDM4C (0.54) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL26036032 | 0.76 | KDM4C (0.46) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL17323672 | 0.76 | KMT2A (0.57) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL25918360 | 0.75 | KDM4C (0.49) | KDM4CNPC1RAB9AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8034819-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034819-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | KDM4C 2166/4885NPC1 237/4885RAB9A 2029/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | KDM4C 2166/4885NPC1 237/4885RAB9A 2029/4885 |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | GCK, GCKR, GALK1 | KDM4C 3351/4885NPC1 2832/4885RAB9A 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.